A Phase II Study of Azacitidine, Venetoclax and Trametinib for Patients With Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
Latest Information Update: 09 Mar 2023
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Trametinib (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 03 Mar 2023 Status changed from recruiting to completed.
- 31 Jul 2020 New trial record